SEC Form PRE 14A filed by Adaptimmune Therapeutics plc
$ADAP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/30/2024 | $4.00 | Buy | H.C. Wainwright |
5/30/2024 | $3.15 | Sector Outperform | Scotiabank |
3/24/2023 | $3.60 | Buy | Bryan Garnier |
1/3/2023 | $5.00 | Neutral → Buy | Guggenheim |
11/9/2022 | $9.00 | Neutral → Buy | Mizuho |
9/22/2021 | $6.00 → $7.00 | Equal-Weight | Wells Fargo |
9/13/2021 | $6.00 → $7.00 | Market Perform | SVB Leerink |
9/7/2021 | $5.00 → $6.00 | Market Perform | SVB Leerink |